Lipopolysaccharide Induces Chronic Kidney Injury and Fibrosis through Activation of mTOR Signaling in Macrophages

Am J Nephrol. 2015;42(4):305-17. doi: 10.1159/000441506. Epub 2015 Oct 31.

Abstract

Background: Septic kidney injury is one of the most common complications in critically ill patients with a high risk of developing chronic kidney disease (CKD). Emerging data indicate that mammalian target of rapamyci (mTOR) signaling plays a major role in septic inflammation by regulating the immune response of macrophage. This study was designed to evaluate the role of mTOR signaling in kidney macrophages during endotoxemia-induced chronic kidney injury and subsequent fibrogenesis.

Methods: Male C57BL/6 mice were used for all animal studies (n=9 for each group). Lipopolysaccharide (LPS) was injected intraperitoneally (1 mg/kg) every 2 days to induce persistent endotoxemia. Rapamycin (1 mg/kg·day) was administered to a subgroup of mice 1 day prior to LPS treatment and continued to termination of the experiment. In ex-vivo experiment, RAW264.7 cells were cultured and treated with LPS (2 µg/ml) for 48 h while a subgroup of cells were incubated in the presence of rapamycin (50 nmol) for 2 h.

Results: Continuous administration of LPS resulted in progressive macrophage infiltration, tubular injury and collagen deposition in mice kidneys. Rapamycin markedly ameliorated LPS-induced kidney pathological changes. Expression of pS6K was rarely observed in normal kidney macrophages, but significantly increased with time by LPS treatment. In ex-vivo study, LPS induced prominent production of IL-1β and MCP-1 in cultured RAW264.7 cells, which was significantly suppressed by rapamycin.

Conclusion: Taken together, our findings show that endotoxemia results in activation of mTOR signaling in macrophages, leading to progressive kidney inflammatory injuries and subsequent fibrosis. Our study may reveal a mechanism involved in the development of sepsis-associated CKD and kidney fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blotting, Western
  • Cell Line
  • Chemokine CCL2 / drug effects*
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Collagen / drug effects
  • Collagen / metabolism
  • Endotoxemia / complications
  • Endotoxemia / metabolism*
  • Endotoxemia / pathology
  • Fibrosis
  • Fluorescent Antibody Technique
  • Immunohistochemistry
  • Immunosuppressive Agents / pharmacology
  • Injections, Intraperitoneal
  • Interleukin-1beta / drug effects*
  • Interleukin-1beta / genetics
  • Interleukin-1beta / metabolism
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / pathology
  • Kidney Tubules / drug effects
  • Kidney Tubules / pathology
  • Lipopolysaccharides / toxicity*
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • RNA, Messenger / drug effects*
  • RNA, Messenger / metabolism
  • Real-Time Polymerase Chain Reaction
  • Renal Insufficiency, Chronic / etiology
  • Renal Insufficiency, Chronic / metabolism*
  • Renal Insufficiency, Chronic / pathology
  • Signal Transduction / drug effects
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases / drug effects*
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Ccl2 protein, mouse
  • Chemokine CCL2
  • IL1B protein, mouse
  • Immunosuppressive Agents
  • Interleukin-1beta
  • Lipopolysaccharides
  • RNA, Messenger
  • Collagen
  • mTOR protein, mouse
  • TOR Serine-Threonine Kinases
  • Sirolimus